Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02570282 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder
A Phase 2 study, sponsored by Strategic Science & Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT02570282 is a Phase 2 study that has completed, run by Strategic Science & Technologies. The registered enrollment target is 31 participants.
The verdict
NCT02570282, a Phase 2 study, has completed, sponsored by Strategic Science & Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a Phase 2, single center, single-dose, double-blind, placebo-controlled, 2-way crossover study to evaluate the safety and efficacy of SST-6007 in women with FSAD. A sufficient number of participants will be enrolled to yield 30 (approximately 15 pre-menopausal and 15 post-menopausal) participants to complete the SST-6007/Placebo Double-Blind, Dosing Phase of the study (Visit 2 and Visit 3).
Interventions
- DRUG Placebo
- DRUG SST-6007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02570282
The ClinicalTrials.gov registry entry for NCT02570282 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Strategic Science & Technologies, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02570282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02570282 about?
NCT02570282 is a clinical study titled "Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder". This is a Phase 2, single center, single-dose, double-blind, placebo-controlled, 2-way crossover study to evaluate the safety and efficacy of SST-6007 in women with FSAD. A sufficient number of participants will be enrolled to yield 30 (approximately 15 pre-menopausal and 15 post-menopausal) partici...
What is the current status of trial NCT02570282?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2015-09. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02570282?
The interventions under investigation include: Placebo (DRUG), SST-6007 (DRUG).
Who is sponsoring clinical trial NCT02570282?
This trial is sponsored by Strategic Science & Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.